» Articles » PMID: 11741910

Substrate and Inhibitor Profile of BACE (beta-secretase) and Comparison with Other Mammalian Aspartic Proteases

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2001 Dec 14
PMID 11741910
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

The full-length and ectodomain forms of beta-site APP cleavage enzyme (BACE) have been cloned, expressed in Sf9 cells, and purified to homogeneity. This aspartic protease cleaves the amyloid precursor protein at the beta-secretase site, a critical step in the Alzheimer's disease pathogenesis. Comparison of BACE to other aspartic proteases such as cathepsin D and E, napsin A, pepsin, and renin revealed little similarity with respect to the substrate preference and inhibitor profile. On the other hand, these parameters are all very similar for the homologous enzyme BACE2. Based on a collection of decameric substrates, it was found that BACE has a loose substrate specificity and that the substrate recognition site in BACE extends over several amino acids. In common with the aspartic proteases mentioned above, BACE prefers a leucine residue at position P1. Unlike cathepsin D etc., BACE accepts polar or acidic residues at positions P2'0 and P1 but prefers bulky hydrophobic residues at position P3. BACE displays poor kinetic constants toward its known substrates (wild-type substrate, SEVKM/DAEFR, K(m) = 7 microm, K(cat) = 0.002 s(-1); Swedish mutant, SEVNL/DAEFR, K(m) = 9 microm, K(cat) = 0.02 s(-1)). A new substrate (VVEVDA/AVTP, K(m) = 1 microm, K(cat) = 0.004) was identified by serendipity.

Citing Articles

Serum β-secretase 1 (sBACE1) activity in subjective cognitive decline: an exploratory study.

Cervellati C, Trentini A, Rosta V, Passaro A, Brombo G, Renzini C Geroscience. 2025; .

PMID: 39828771 DOI: 10.1007/s11357-025-01523-x.


Cholesterol and Lipid Rafts in the Biogenesis of Amyloid-β Protein and Alzheimer's Disease.

Pantelopulos G, Abraham C, Straub J Annu Rev Biophys. 2024; 53(1):455-486.

PMID: 38382114 PMC: 11575466. DOI: 10.1146/annurev-biophys-062823-023436.


Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.

Morato X, Pytel V, Jofresa S, Ruiz A, Boada M Int J Mol Sci. 2022; 23(16).

PMID: 36012569 PMC: 9409252. DOI: 10.3390/ijms23169305.


A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria.

Barber J, Sikakana P, Sadler C, Baud D, Valentin J, Roberts R Toxicol Res (Camb). 2021; 10(2):203-213.

PMID: 33884171 PMC: 8045587. DOI: 10.1093/toxres/tfaa106.


Interaction of Cucurbit[7]uril With Protease Substrates: Application to Nanosecond Time-Resolved Fluorescence Assays.

Hennig A, Nau W Front Chem. 2020; 8:806.

PMID: 33134264 PMC: 7511663. DOI: 10.3389/fchem.2020.00806.